Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer – guidance (TA643)
Entrectinib is recommended as an option for treating ROS1-positive advanced non-small-cell lung cancer in adults who have not had ROS1 inhibitors.
Source:
National Institute for Health and Care Excellence